دورية أكاديمية
أعرض في EDS

Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results.

التفاصيل البيبلوغرافية
العنوان: Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results.
المؤلفون: Chick RC; Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA., Gunderson AJ; Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA., Rahman S; Department of Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA., Cloyd JM; Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
المصدر: Cancers [Cancers (Basel)] 2023 Aug 04; Vol. 15 (15). Date of Electronic Publication: 2023 Aug 04.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease due to its late presentation and tendency to recur early even after optimal surgical resection. Currently, there are limited options for effective systemic therapy. In addition, PDAC typically generates an immune-suppressive tumor microenvironment; trials of immunotherapy in metastatic PDAC have yielded disappointing results. There is considerable interest in using immunotherapy approaches in the neoadjuvant setting in order to prime the immune system to detect and prevent micrometastatic disease and recurrence. A scoping review was conducted to identify published and ongoing trials utilizing preoperative immunotherapy. In total, 9 published trials and 27 ongoing trials were identified. The published trials included neoadjuvant immune checkpoint inhibitors, cancer vaccines, and other immune-modulating agents that target mechanisms distinct from that of immune checkpoint inhibition. Most of these are early phase trials which suggest improvements in disease-free and overall survival when combined with standard neoadjuvant therapy. Ongoing trials are exploring various combinations of these agents with each other and with chemotherapy and/or radiation. Rational combination immunotherapy in addition to standard neoadjuvant therapy has the potential to improve outcomes in PDAC, but further clinical trials are needed, particularly those which utilize an adaptive trial design.
References: Pancreas. 2012 Apr;41(3):409-15. (PMID: 22158072)
Br J Surg. 2022 Dec 13;110(1):34-42. (PMID: 36346716)
Front Immunol. 2023 Feb 23;14:1133207. (PMID: 36911692)
Cell. 2023 Mar 16;186(6):1127-1143.e18. (PMID: 36931243)
Int J Mol Sci. 2021 Nov 27;22(23):. (PMID: 34884642)
Expert Rev Clin Immunol. 2016 Dec;12(12):1347-1357. (PMID: 27323245)
Am J Clin Oncol. 2019 Oct;42(10):755-760. (PMID: 31513018)
J Immunother. 2015 Jan;38(1):1-11. (PMID: 25415283)
Nat Med. 2022 Jun;28(6):1167-1177. (PMID: 35662283)
Cancer Immunol Immunother. 2008 Oct;57(10):1559-68. (PMID: 18618110)
Nature. 2022 Nov;611(7936):603-613. (PMID: 36352230)
JAMA. 2021 Sep 7;326(9):851-862. (PMID: 34547082)
Clin Cancer Res. 2022 Nov 1;28(21):4606-4617. (PMID: 35775964)
Eur J Cancer. 2023 Jul;188:90-97. (PMID: 37229836)
JAMA Netw Open. 2021 Mar 1;4(3):e211031. (PMID: 33688961)
Cell Rep Med. 2023 Mar 21;4(3):100972. (PMID: 36889321)
Cancer Lett. 2021 Apr 28;504:1-14. (PMID: 33549709)
Clin Cancer Res. 2021 Mar 1;27(5):1278-1286. (PMID: 33277370)
Oncoimmunology. 2021 Mar 17;10(1):1900635. (PMID: 33796412)
JAMA Oncol. 2021 Mar 1;7(3):421-427. (PMID: 33475684)
Onco Targets Ther. 2021 Jun 01;14:3537-3544. (PMID: 34103944)
Hepatobiliary Surg Nutr. 2021 Aug;10(4):534-537. (PMID: 34430537)
Am Soc Clin Oncol Educ Book. 2016;35:e159-67. (PMID: 27249718)
Lancet Oncol. 2016 May;17(5):651-62. (PMID: 27055731)
Nature. 2020 Jan;577(7791):549-555. (PMID: 31942075)
HPB (Oxford). 2020 Nov;22(11):1569-1576. (PMID: 32063480)
Cancer Discov. 2021 Jun;11(6):1353-1367. (PMID: 33712487)
J Hosp Med. 2019 Jun 19;14(7):416-418. (PMID: 31251164)
Nature. 2017 Nov 23;551(7681):512-516. (PMID: 29132146)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
J Exp Med. 2022 May 2;219(5):. (PMID: 35404390)
Discov Med. 2018 Sep;26(142):85-92. (PMID: 30399326)
Nat Med. 2018 Nov;24(11):1645-1648. (PMID: 30401867)
Nat Med. 2020 Jun;26(6):878-885. (PMID: 32451495)
Vaccine. 2015 Dec 16;33(51):7386-7392. (PMID: 26392010)
JCI Insight. 2022 Nov 22;7(22):. (PMID: 36509285)
Clin Cancer Res. 2020 Jul 15;26(14):3578-3588. (PMID: 32273276)
Lancet. 2020 Jun 27;395(10242):2008-2020. (PMID: 32593337)
Oncoimmunology. 2015 May 29;4(12):e1054599. (PMID: 26587332)
Cancer Biol Med. 2015 Sep;12(3):201-8. (PMID: 26487965)
J Clin Oncol. 2020 Jan 1;38(1):1-10. (PMID: 31682550)
Cancer Immunol Res. 2014 Jul;2(7):616-31. (PMID: 24942756)
Nat Rev Clin Oncol. 2023 May;20(5):318-337. (PMID: 36932224)
Ann Surg. 2020 Sep 1;272(3):481-486. (PMID: 32740235)
Immunotherapy. 2022 Mar;14(4):189-199. (PMID: 34984928)
Ann Surg Oncol. 2021 Aug;28(8):4098-4099. (PMID: 33987757)
Nat Commun. 2023 Jun 20;14(1):3650. (PMID: 37339979)
Front Immunol. 2022 Sep 26;13:956984. (PMID: 36225934)
Lancet Oncol. 2017 Mar;18(3):e143-e152. (PMID: 28271869)
Cancer Cell. 2020 Dec 14;38(6):788-802. (PMID: 32946773)
J Clin Oncol. 2022 Aug 20;40(24):2789-2805. (PMID: 35839445)
Front Immunol. 2022 Sep 13;13:998620. (PMID: 36177019)
J Surg Oncol. 2021 May;123(6):1432-1440. (PMID: 33831253)
Cancer Med. 2021 Jul;10(13):4302-4311. (PMID: 33982452)
N Engl J Med. 2022 Jun 2;386(22):2112-2119. (PMID: 35648703)
Cancer Immunol Immunother. 2021 May;70(5):1465-1474. (PMID: 33180182)
JAMA Oncol. 2019 Oct 01;5(10):1431-1438. (PMID: 31318392)
J Immunother Cancer. 2023 Jan;11(1):. (PMID: 36609489)
Ann Surg. 2022 Jan 1;275(1):45-53. (PMID: 33630475)
Nature. 2023 Jun;618(7963):144-150. (PMID: 37165196)
Nat Cancer. 2023 Jan;4(1):62-80. (PMID: 36585453)
Br J Cancer. 2015 May 26;112(11):1782-90. (PMID: 25942397)
Clin Cancer Res. 2021 Aug 15;27(16):4574-4586. (PMID: 34112709)
فهرسة مساهمة: Keywords: cancer vaccine; clinical trial; immune checkpoint inhibitor; immunotherapy; neoadjuvant; pancreatic cancer; review
تواريخ الأحداث: Date Created: 20230812 Latest Revision: 20230814
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10416846
DOI: 10.3390/cancers15153967
PMID: 37568782
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers15153967